SOLICITATION NOTICE
65 -- Marburg virus (MARV) and Sudan virus (SUDV) Vaccines
- Notice Date
- 7/31/2025 12:35:26 PM
- Notice Type
- Solicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- BARDA - ASPR / DAAPPO / BARDA DCMA WASHINGTON DC 20515 USA
- ZIP Code
- 20515
- Solicitation Number
- 75A50125R00006
- Response Due
- 8/27/2025 11:00:00 AM
- Archive Date
- 09/11/2025
- Point of Contact
- Yifan Yang, Greg Smith
- E-Mail Address
-
yifan.yang@hhs.gov, greg.smith1@hhs.gov
(yifan.yang@hhs.gov, greg.smith1@hhs.gov)
- Small Business Set-Aside
- NONE No Set aside used
- Description
- The 2014 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan identifies Ebola virus and Marburg virus as high-priority threats as determined by the Department of Homeland Security to present a material threat to national security. Strategies to mitigate the threat of Ebola virus and Marburg virus include the development of vaccines suitable for protection against Ebola and Marburg virus disease respectively. BARDA is seeking vaccines that can be safely and effectively used for the U.S. civilian population in individuals with an elevated risk of exposure to Sudan virus (SUDV) and Marburg virus (MARV). This acquisition will allow BARDA to invest Project BioShield funds for the advanced development, US Food and Drug Administration (FDA) licensure, procurement, shipping, and vendor managed inventory (VMI) storage of MARV and SUDV monovalent vaccines.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/fba2112d7da54dc49033b9adbe509953/view)
- Place of Performance
- Address: Washington, DC, USA
- Country: USA
- Country: USA
- Record
- SN07532460-F 20250802/250801000110 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |